Analysis of glycosphingolipids from human cerebrospinal fluid

David A Priestman, Reuben Bush, Maria Leondaraki, Danielle te Vruchte, Kerri-Lee Wallom, María E Fernández-Suárez, Frances M Platt

Published: 2023-02-21 DOI: 10.17504/protocols.io.5qpvorrndv4o/v1

Abstract

Interest in the role of cellular glycosphingolipids (GSLs) in health and disease led to us developing a sensitive method to analyse the full complement of GSL structures present in mammalian cells, fluids and tissues. The original qualitative method we developed was published in 2004 and measured the oligosaccharides selectively released from glycosphingolipids using a ceramide glycanase enzyme derived from the medicinal leech. We have now updated and refined this protocol with the focus on achieving sensitive and reproducible quantitation of GSLs in control and patient cerebrospinal fluid samples. The method uses the fluorescent compound anthranilic acid (2-AA) to label oligosaccharides prior to analysis using normal-phase high-performance liquid chromatography. The labelling procedure is rapid, selective, and easy to perform. With the inclusion of a 2AA-labelled chitotriose calibration standard, it is possible to obtain accurate and reproducible molar quantities of individual GSL species.

Before start

Check that you have the required reagents, solvents, chemicals, equipment and PPE.

Steps

GSL preparation from cerebrospinal fluid

1.

Use 100µL cerebrospinal fluid for GSL quantification.

2.

Add 100µL de-ionised water to make the volume up to 200µL in a 1.5 ml screw-cap tube.

3.

Add 0.8mL of chloroform/methanol (1:2, v/v) to give (C/M/W 4:8:3 final).

Safety information
Chloroform and methanol are very toxic, and methanol is flammable. Refer to the Safety Data Sheets.

4.

Leave at 4°C for 16h 0m 0s

5.

Vortex.

6.

Separate into two phases: by adding 0.2mL PBS and then 0.2mL chloroform.

7.

Vortex.

8.

Centrifuge at 16,000 x g for 0h 10m 0s at room temperature.

9.

Remove very carefully the lower phase to a new tube and retain the upper phase.

10.

Dry down the lower phase under a stream of (oxygen-free) nitrogen in heating block (42°C).

11.

When dry, re-suspend the lower phase in 20µL chloroform/methanol (1:3).

12.

Add upper phase to lower phase and vortex.

13.

Pre-equilibrate C18 columns (telos, Kinesis, UK) with 4 x 1mL methanol and 3 x 1mL deionised water.

14.

Load lower/upper phase mix onto column, let drip through gravity flow.

15.

Rinse sample tube with 1mL water, apply to column to wash.

16.

Wash column with 3 x 1mL water.

17.

Elute GSLs into a new tube with:

17.1.

2mL chloroform/methanol (98:2). Push through first 0.5mL. You can use syringe with adapter that fits into top of column.

17.2.

2mL chloroform/methanol (1:3).

17.3.

1mL methanol.

18.

Vortex and leave 0h 10m 0sat 4°C or carry on to enzymatic digestion.

GSL digestion with EGC’ase I

19.

Vortex (5mL, C18) and dry down samples under a stream of nitrogen in heating block (42°C).

20.

When about 150µL sample remaining, transfer to 1.5mL screw-cap tube.

21.

Rinse sample tube with 200µL C:M 2:1, vortex and combine with the rest of the sample in the screw-cap tube.

22.

Rinse sample tube with 200µL chloroform, vortex and combine with the rest of the sample in the screw-cap tube.

23.

Dry down, under a slow stream of nitrogen in heating block (42°C).

24.

Re-suspend in 200µL C:M 2:1, vortex, dry down under a very slow stream of nitrogen.

25.

Re-suspend in 50µL C:M 2:1, vortex, dry down under a very slow stream of nitrogen.

Note
NB It is essential that ALL the sample is dried in the bottom of the tube.

26.

Add 90µL enzyme/buffer to each sample and vortex:

26.1.

rEGCase : 5µL enzyme (stored in freezer) plus 85µL buffer per sample.

26.2.

rEGCase buffer (stored at 4°C): 0.6 % Triton in 50millimolar (mM) sodium acetate pH 5.2.

27.

Incubate at 37°C for 16h 0m 0s.

Note
rEGCaseI: recombinant Endoglycoceramidase I was custom synthesised by GenScript.

2AA labelling of glycans released from GSLs

28.

Note
Labelling mix : 30 mg/mL 2AA in labelling buffer and 45 mg/mL sodium cyanoborohydrideLabelling buffer : 4% sodium acetate trihydrate and 2% boric acid in methanol

Dissolve 2AA in labelling buffer first with vortexing.

29.

Add 2AA in buffer to sodium cyanoborohydride and vortex.

Safety information
Sodium cyanoborohydride is very toxic. Refer to the Safety Data Sheet.

30.

Add 310µL labelling mix to the 90µL sample (digest) in 1.5mL screw-cap tube.

31.

Incubate in oven at 80°C for 1h 0m 0s, vortexing at 0h 30m 0s.

32.

Allow to cool to 80Room temperature.

33.

Add 1mL acetonitrile:water (97:3).

34.

Transfer from screw-cap tube to 15mL tubes.

35.

Rinse screw-cap tube with 2 x 1mL acetonitrile:water (97:3) and add to 15mLtube.

36.

Pre-equilibrate 50 mg Discovery® DPA-6S SPE Tube (supplied by Sigma-Aldrich) with:

1mL acetonitrile

2 x 1mL water

2 x 1mL acetonitrile

37.

Apply samples (3.4mL) to equilibrated DPA-6S columns, let drip through gravity flow.

38.

Wash columns with acetonitrile:water (95:5) → add 1mL into the 15mL tubes to wash and add to columns, and then add 3 x 1mL acetonitrile:water (95:5) directly onto the columns.

39.

Elute with 600µL water into new tubes.

40.

Dry down under a slow stream of nitrogen in a heating block (42°C ).

41.

Resuspend in 60µL of 70:30 acetonitrile:water

42.

For HPLC, inject 50µL.

HPLC protocol

43.

The HPLC system consists of a Waters Alliance 2695 separations module and an in-line Waters 2475 multi λ-fluorescence detector set at Ex λ360 nm and Em λ425 nm.

44.

Purified 2AA-labeled oligosaccharides are separated and quantified by normal-phase high-performance liquid chromatography (NP-HPLC) as previously described (Neville et al. , 2004, see the reference below).

Note
Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labelingDCA Neville, V Coquard, DA Priestman, DJM te Vruchte, DJ Sillence, Raymond A Dwek, Frances M Platt, Terry D ButtersAnalytical biochemistry 331 (2), 275-282, (2004). doi: 10.1016/j.ab.2004.03.051.

45.

The solid phase used is a 4.6 × 250 mm TSK gel-Amide 80 column maintained at 30°C (Anachem, Luton, UK).

46.

The chromatographic flow rate is 0.8 mL/min, and run time was 60 min. The total run time is 1h 0m 0s.

Gradient conditions for Normal Phase HPLC. All chromatography was controlled and data were collected and processed using Waters Empower software.
Gradient conditions for Normal Phase HPLC. All chromatography was controlled and data were collected and processed using Waters Empower software.
47.

The mobile phases are acetonitrile (solvent A), de-ionised water (solvent B) and 100millimolar (mM) ammonium acetate, 3.85 (solvent C).

48.

Starting conditions are 71.6% solvent A. 8.4% solvent B and 20% solvent C at 0.8 mL/min constant flow-rate for 6 mins. 0h 6m 0s

49.

The gradient is developed from 6 min to 35 min by increasing solvent B from 8.4% to 27.2% with concomitant decrease in solvent A from 71.6% to 52.8 %. 0h 29m 0s

50.

From 35 to 37 min solvent B is increased to 57% and solvent A reduced to 23%, then maintained for 2 min up until 39 min. 0h 4m 0s

51.

Between 39 and 41 min the solvent ratios are returned to the starting conditions and then maintained for 1 min. 0h 3m 0s

52.

At 42 mins the flow-rate is increased to 1.2 mL/min and maintained for 12 min up to 54 min. 0h 12m 0s

53.

Between 54 and 60 min the flow-rate is gradually returned to 0.8 mL/min. 0h 6m 0s

54.

Individual GSL species are identified by their glucose unit values (GUs), calculated with the HPLC Empower software using a homopolymer dextran ladder (Fig. 2).

54.1.

To help identify GSL peaks in the CSF samples, compare the GUs of the peaks in the CSF samples with those in a GSL standard mix.

54.2.

Prepare a mixture of commercially available authentic GSLs in a screw-cap tube:

50µL Matreya Neutral GSL mix Cat No 1505 (Glc-Cer, Lac-Cer, Gb3, Gb4) 1.0 mg/ml

100µLMatreya Ganglioside mix Cat No 1510 (Lac-Cer, GM3, GD3) 0.5 mg/ml

100µL Matreya Ganglioside mix Cat No 1511 (GA1, GM1a, GD1a, GD1b,GT1b) 0.5 mg/ml

30µLMatreya GM2 Ganglioside Cat No 1502 (GM2) 0.5 mg/ml

30µLSigma Asialo-GM2 Cat No G9398 (GA2) 1.0 mg/ml

54.3.

Dry down the mixture under nitrogen and then digest, label and clean up as done for the CSF samples in steps 25-41.

54.4.

Aliquot and store at-20°C.

54.5.

In order to calculate molar quantities from integrated peaks in the chromatogram, inject a calibration standard containing 2.5 pmol 2AA-labelled chitotriose (Ludger) with each sample set (not shown).

Figures 1- 5: HPLC profile and sugar structures for GSLs in cerebrospinal fluid together with the GSL biosynthetic pathway

55.
Figure 1  HPLC profiles for GSL standards and 2AA-labelled homopolymer dextran ladder. Glucose Units were calculated using the retention times of a 2AA-labelled homopolymer dextran ladder and are shown for each of the GSL standard peaks.
Figure 1 HPLC profiles for GSL standards and 2AA-labelled homopolymer dextran ladder. Glucose Units were calculated using the retention times of a 2AA-labelled homopolymer dextran ladder and are shown for each of the GSL standard peaks.
Figure 2 GSL biosynthesis. Biosynthetic enzymes genes are indicated in the blue grid. Ganglioside names are abbreviated according to Svennerholm [1].  [1] L. Svennerholm, Designation and schematic structure of gangliosides and allied glycosphingolipids, Prog Brain Res 101 (1994) XI-XIV.
Figure 2 GSL biosynthesis. Biosynthetic enzymes genes are indicated in the blue grid. Ganglioside names are abbreviated according to Svennerholm [1]. [1] L. Svennerholm, Designation and schematic structure of gangliosides and allied glycosphingolipids, Prog Brain Res 101 (1994) XI-XIV.
Figure 3 Typical HPLC profile for 2AA-labelled glycans released from ante-mortem human CSF glycosphingolipids with sugar structures indicated for each peak. In order to calculate values for total GSL concentrations, use the sum of the areas for all peaks from LacCer to GQ1b. GlcCer, which elutes before LacCer, is not included because it is not fully hydrolysed by EGC’ase I.
Figure 3 Typical HPLC profile for 2AA-labelled glycans released from ante-mortem human CSF glycosphingolipids with sugar structures indicated for each peak. In order to calculate values for total GSL concentrations, use the sum of the areas for all peaks from LacCer to GQ1b. GlcCer, which elutes before LacCer, is not included because it is not fully hydrolysed by EGC’ase I.
Figure 4 Typical HPLC profile for 2AA-labelled glycans released from post-mortem human CSF glycosphingolipids with sugar structures indicated for each peak. In order to calculate values for total GSL concentrations, use the sum of the areas for all peaks from LacCer to GQ1b. GlcCer, which elutes before LacCer, is not included because it is not fully hydrolysed by EGC’ase I.
Figure 4 Typical HPLC profile for 2AA-labelled glycans released from post-mortem human CSF glycosphingolipids with sugar structures indicated for each peak. In order to calculate values for total GSL concentrations, use the sum of the areas for all peaks from LacCer to GQ1b. GlcCer, which elutes before LacCer, is not included because it is not fully hydrolysed by EGC’ase I.
Figure 5 Overlay of typical HPLC profiles for 2AA-labelled glycans released from human: plasma, post-mortem CSF, and ante-mortem CSF. Due to breakdown of the blood-cerebrospinal fluid barrier, post-mortem CSF is characterised by significant increases in GSLs that are prevalent in plasma, notably, GM3 and Gb3.
Figure 5 Overlay of typical HPLC profiles for 2AA-labelled glycans released from human: plasma, post-mortem CSF, and ante-mortem CSF. Due to breakdown of the blood-cerebrospinal fluid barrier, post-mortem CSF is characterised by significant increases in GSLs that are prevalent in plasma, notably, GM3 and Gb3.

Note
Figures created with Figures created with BioRender.com

推荐阅读

Nature Protocols
Protocols IO
Current Protocols
扫码咨询